Overview
Actos bladder cancer lawsuits — MDL 2299, In re Actos (Pioglitazone) Products Liability Litigation, W.D. La., Judge Rebecca F. Doherty (per JPML). Plaintiffs alleged Actos (pioglitazone, Takeda) increased their risk of bladder cancer (per complaints). The FDA issued a public safety announcement in 2011 (per FDA), and IARC classified pioglitazone as a Group 1 carcinogen (per IARC Monograph 106, 2011). After a first bellwether verdict for a plaintiff (April 2014, per reports), Takeda reached a $2.4 billion global settlement of ~8,000 claims on April 28, 2015 (per public reports). A parallel state-court cluster proceeded in Illinois (per court records). The MDL resolved through the settlement; individual claim payments were administered under the settlement program (per public reports). No further payout amount is available or can be promised.
Status of the science / claims: IARC (WHO) classified pioglitazone as a Group 1 carcinogen in 2011 (per IARC Monograph 106); the FDA issued a safety announcement in 2011 (per FDA). The parties resolved the consolidated litigation through a global settlement in 2015 (per public reports).
Companies involved
Settlement amounts
Global settlement: $2.4 billion for ~8,000 claims (per public reports, April 28, 2015). Individual claim amounts varied widely; per-claim amounts in the hundreds of thousands for the most severe claims were reported (per law firm reports). Amounts are claim-specific; no outcome can be promised.
Case count
| Month | Filed cases | Δ |
|---|---|---|
| Apr 28, 2015 | 8,000 | +4500 |
| Jun 1, 2014 | 3,500 | +2000 |
| Jun 1, 2013 | 1,500 | +1300 |
| Dec 1, 2011 | 200 | — |
Key dates
- April 28, 2015Takeda global settlement: $2.4 billion, ~8,000 claims (per public reports)
- April 25, 2014First bellwether verdict for plaintiff (Allen v. Takeda); nine-figure punitive damages reported (per public reports)
- December 20, 2011MDL 2299 established in W.D. La., Judge Doherty (per JPML)
- March 16, 2011FDA public safety announcement: possible increased bladder-cancer risk with pioglitazone (per FDA)
Updates
- Updated Aug 1, 2026Seeded from research (Aug 31, 2026): MDL 2299 (W.D. La., Judge Doherty); $2.4 billion global settlement, April 28, 2015 (per public reports).
Notable filings
- — Global settlement order — In re Actos MDL 2299 (W.D. La.) [source] — $2.4 billion global settlement of ~8,000 claims (per public reports, April 28, 2015).
FAQ
What is the Actos bladder cancer lawsuit about?
Plaintiffs alleged Actos (pioglitazone, Takeda) increased their risk of bladder cancer (per complaints). The MDL was In re Actos (Pioglitazone) Products Liability Litigation, MDL 2299, W.D. La., Judge Rebecca F. Doherty (per JPML).
How much did the settlement pay?
Takeda reached a $2.4 billion global settlement resolving about 8,000 claims on April 28, 2015 (per public reports).
How much did individual claims pay?
Per-claim amounts varied widely by injury and stage. Per law firm reports, the most severe claims resolved in the hundreds of thousands; no outcome or amount can be promised for any individual.
Was there a verdict at trial?
Yes — a first bellwether verdict for a plaintiff was reported in April 2014, before the global settlement (per reports).
What did regulators and agencies conclude?
The FDA issued a public safety announcement in 2011 (per FDA), and IARC classified pioglitazone as a Group 1 carcinogen (per IARC Monograph 106, 2011).
Can I still file an Actos claim?
The claims process under the 2015 global settlement is closed (per the settlement administrator). If you believe you have a late or separate claim, consult a licensed attorney — this page is reference only.
Think this matters to you?
This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.
Start free case review →